HIV & TB: An R&D tale of two vaccines
Wednesday, January 27, 2021
•
SA03
•
6:45 PM
>
8:15 PM
•
HIV & TB: An R&D tale of two vaccines
•
Satellite Channel 2
The HIV epidemic, entering its fourth decade, has affected 75.7 million people and led to 32.7 million deaths. Much progress has been made in developing effective treatments and improving prevention options, but the challenge of developing a safe and globally effective vaccine persists. HIV incidence has remained unchanged for over 10 years, disproportionally affecting populations in sub-Saharan Africa, with UNAIDS targets far from being reached.<br>Meanwhile, tuberculosis (TB) remains the leading cause of death from an infectious disease, with Africa accounting for nearly 70% of TB and 27% of TB cases among people living with HIV globally. Poor diagnostics and linkage to care, in conjunction with multidrug-resistant TB, make TB a public health crisis and health security threat.<br>For HIV and TB, the need for universally effective vaccines has never been more urgent as public health systems struggle with the growing cost of these epidemics and threats of new pandemics, such as COVID-19, affecting prevention and treatment. While the HIV vaccine field is still exploring multiple strategies, the TB vaccine field has found a new hope with BCG and M72/ASO1E.<br>Although the two epidemics affect overlapping populations and their vaccine R&D faces similar struggles, the two fields seldom interact on solving common challenges. Conversely, the SARS-Co-V2 pandemic is benefiting from decades of HIV and TB vaccine R&D with many HIV stakeholders having pivoted to COVID-19.<br>Co-sponsored by the Global HIV Vaccine Enterprise and the TB Vaccine Initiative (TBVI), this satellite will examine lessons learned from each R&D journey and look to a future in which integrated research supports product development. It will explore the role of the industry, how to develop mutually beneficial academic-industry relationships, and funding structures and mechanisms that create a sustainable R&D environment.
6:45 PM
•
SA03.01
•
Where and how can we work together to address shared issues and hasten product development?
See abstract
7:20 PM
•
SA03.02
•
Is an integrated approach possible for a long-term effort?
See abstract
7:55 PM
•
SA03.03
•
Introductory Remarks
See abstract
|